ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors.
ACE
COVID-19
Insertion/deletion
Polymorphism
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
27
04
2021
revised:
29
04
2021
accepted:
29
04
2021
pubmed:
7
5
2021
medline:
22
6
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID-19, with I/I homozygotes being at increased risk of symptomatic COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality.
METHODS
METHODS
In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects.
RESULTS
RESULTS
The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76).
CONCLUSIONS
CONCLUSIONS
We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID-19, with I/I homozygotes being at increased risk of symptomatic COVID-19.
Identifiants
pubmed: 33957095
pii: S0009-8981(21)00149-2
doi: 10.1016/j.cca.2021.04.024
pmc: PMC8091801
pii:
doi:
Substances chimiques
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206-209Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Hum Genomics. 2020 Sep 11;14(1):30
pubmed: 32917282
Gene. 2020 Oct 20;758:144944
pubmed: 32628976
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Atherosclerosis. 2010 Aug;211(2):676-81
pubmed: 20471016
Herz. 2000 Feb;25(1):1-6
pubmed: 10713904
Infect Genet Evol. 2021 Jul;91:104801
pubmed: 33676010
ERJ Open Res. 2021 Apr 19;7(2):
pubmed: 33889638
Heart. 2020 Oct;106(19):1503-1511
pubmed: 32737124
Clin Chem. 2004 Sep;50(9):1683-6
pubmed: 15331509
J Cell Physiol. 2021 Jan;236(1):49-54
pubmed: 32542735
Clin Chim Acta. 2020 Nov;510:455-458
pubmed: 32791137
Med Sci Monit. 2000 May-Jun;6(3):503-6
pubmed: 11208361
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Front Biosci (Elite Ed). 2021 Jan 1;13(1):117-139
pubmed: 33048778
Physiol Res. 2021 Mar 17;70(1):111-115
pubmed: 33728925
Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):484-92
pubmed: 10669647
J Mol Med (Berl). 2020 Nov;98(11):1505-1509
pubmed: 32935155
Clin Microbiol Rev. 2020 Jun 24;33(4):
pubmed: 32580969
Clin Chem Lab Med. 2020 Jun 25;58(7):1125-1126
pubmed: 32286246
Am J Hum Genet. 1988 Nov;43(5):774-80
pubmed: 2847529
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Clin Chim Acta. 2020 Jun;505:192-193
pubmed: 32220422
Nucleic Acids Res. 1992 Mar 25;20(6):1433
pubmed: 1313972
Clin Chim Acta. 2010 Aug 5;411(15-16):1069-72
pubmed: 20362563
J Public Health (Oxf). 2020 Aug 18;42(3):451-460
pubmed: 32556213
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Mol Endocrinol. 1996 Aug;17(1):27-30
pubmed: 8863184
Clin Chem Lab Med. 2020 Jun 25;58(7):1127-1128
pubmed: 32386188
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1315-1316
pubmed: 32755828
Immunol Rev. 2020 Jul;296(1):205-219
pubmed: 32658335